Jazz Pharmaceuticals appoints Patrick Kennedy to Board; Peter Gray not standing for re-election

Jazz Pharmaceuticals plc

Patrick Kennedy appointed as Class I director effective March 1, 2024; term expires at 2024 AGM.
Kennedy will serve on the Audit Committee; receives standard non-employee director compensation.
Peter Gray notified the Board he will not stand for re-election at the 2024 Annual Meeting, with no disagreement with the Company.
Kennedy entered into Jazz's standard indemnification agreement for directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Gray

Director

JAZZ · Jazz Pharmaceuticals plc

Filed: February 27, 2024, 6:59 PM ET

Peter Gray notified the Board that he will not stand for re-election to the Board, when his term expires, at the 2024 Annual Meeting.

Appointed

Patrick Kennedy

Director

JAZZ · Jazz Pharmaceuticals plc

Effective: 2024-03-01
Filed: February 27, 2024, 6:59 PM ET

appointed Patrick Kennedy to the Board, effective as of March 1, 2024, as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Gray resigned as Director at Jazz Pharmaceuticals plc.

Action: resigned
Role: Director

Exact text from the filing

Peter Gray notified the Board that he will not stand for re-election to the Board, when his term expires, at the 2024 Annual Meeting.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick Kennedy was appointed as Director at Jazz Pharmaceuticals plc.

Action: appointed
Role: Director

Exact text from the filing

appointed Patrick Kennedy to the Board, effective as of March 1, 2024, as a Class I director

View on SEC.gov

Jazz Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001193125-24-047087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.